Pénfigo eritematoso severo asociado a falla cutánea tratado exitosamente con rituximab.

Pemphigus erythematosus (PE) is a rare disorder that belongs to a group of chronic autoimmune blistering diseases. It is a form of pemphigus with an overlapping clinical and immunological presentation of pemphigus foliaceus and lupus erythematosus, mediated by autoantibodies targeting desmoglein 1. It has a broad clinical spectrum, and severe cases can result in multi-organ compromise. To date, there is no established treatment for severe cases of PE. We describe a case of a previously healthy patient with a 4-month clinical course of generalized painful erythematous desquamative plaques and blisters, associated with a 10 kg weight loss. The clinical and histopathological findings were consistent with PE. An adjusted rituximab protocol was used, achieving disease remission within 20 days. Rituximab is the mainstay of therapy and a well-known effective treatment for pemphigus vulgaris with a prolonged remission; nevertheless, there are no established protocols and limited evidence in PE. [ABSTRACT FROM AUTHOR]